Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | NMT2 | O60551 | 1/20 | 0.39 |
| ▸ | NMT1 | P30419 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3875764 | 1.00 | MAPT (0.44) | MAPTMEN1KMT2AEGLN2EGLN1 | |
| SCHEMBL4062749 | 0.94 | MEN1 (0.42) | MAPTMEN1KMT2AEGLN2EGLN1 | |
| SCHEMBL1486808 | 0.93 | MAPT (0.46) | MAPTMEN1KMT2AEGLN2EGLN1 | |
| SCHEMBL1486807 | 0.93 | MAPT (0.46) | MAPTMEN1KMT2AEGLN2EGLN1 | |
| SCHEMBL1486584 | 0.91 | MEN1 (0.42) | MAPTMEN1KMT2AEGLN2EGLN1 | |
| SCHEMBL5618323 | 0.90 | MAPT (0.40) | MAPTMEN1KMT2AEGLN2EGLN1 | |
| SCHEMBL1486472 | 0.89 | TDO2 (0.42) | MAPTMEN1KMT2ABACE1NPC1 | |
| SCHEMBL1486475 | 0.88 | AR (0.42) | MAPTMEN1KMT2AEGLN2EGLN1 | |
| SCHEMBL1486671 | 0.87 | MAPT (0.40) | MAPTMEN1KMT2AEGLN2EGLN1 | |
| SCHEMBL1486672 | 0.87 | MAPT (0.40) | MAPTMEN1KMT2AEGLN2EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1658076-B1 | ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20090018122-A1 | Aryloxy and Arylalkyleneoxy Substituted Imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018122-A1 | Aryloxy and Arylalkyleneoxy Substituted Imidazoquinolines | IL2, IFNG, IRF3 | MAPT 4765/4885MEN1 4690/4885KMT2A 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.